Rocavorexant (INNTooltip International Nonproprietary Name; developmental code names C4X-3256 and INDV-2000) is an orexin OX1 receptor antagonist which is under development for the treatment of opioid-related disorders and other substance-related disorders. It is taken orally. The drug is under development by C4X Discovery and/or Indivior. As of May 2026, development for all indications has been suspended. The drug has reached phase 2 clinical trials for opioid-related disorders and phase 1 trials for substance-related disorders.
See also List of investigational substance-related disorder drugs
References


